These findings are in keeping with the results obtained in cultures from UCMD patients [14] and in fibers from Col6a1−/− mice [12], and they indicate that, at the dose used in this study, CsA reaches pharmacologically active concentrations in muscle. The gene discussed is COL6A1; the disease is Ullrich congenital muscular dystrophy.